Psoriatic arthritis is a chronic inflammatory disease in which the immune system attacks the joints, tendons, and skin simultaneously. It develops in roughly 20% of people who have psoriasis, though it occasionally appears in people with no visible skin involvement. The condition can affect any joint in the body, and without treatment, it can cause permanent joint damage.
How the Immune System Drives the Disease
In a healthy body, the immune system defends against infections and heals injuries. In psoriatic arthritis, that system loses its ability to distinguish the body’s own tissue from a threat. The process starts with a breakdown in immune tolerance: the barrier lining of tissues becomes disrupted, and immune cells begin migrating into joints, tendons, and skin where they don’t belong.
Once there, these immune cells release waves of inflammatory signaling molecules. The most important of these trigger a specific type of immune cell that pumps out even more inflammatory signals, creating a self-reinforcing cycle. This cascade does two kinds of damage at once. Certain signals activate cells that break down bone and cartilage, causing the erosion and joint narrowing that show up on X-rays. Other signals paradoxically stimulate abnormal new bone growth at tendon attachment points, which is one reason psoriatic arthritis looks different from other forms of arthritis on imaging. The same inflammatory process happening in skin cells produces the raised, scaly patches of psoriasis.
Recognizing the Symptoms
Psoriatic arthritis produces a distinctive combination of joint, tendon, skin, and nail symptoms. Not everyone gets all of them, and they can appear in any order over months or years.
Joint pain and stiffness are the most common complaints. Unlike rheumatoid arthritis, which tends to affect the same joints on both sides of the body, psoriatic arthritis is often asymmetric, particularly early on. It frequently targets the small joints closest to the fingertips and toenails, along with larger joints in the knees and ankles. The lower back and sacroiliac joints can also be involved, causing inflammatory back pain that’s typically worse in the morning and improves with movement.
One of the hallmark signs is dactylitis, often called “sausage digits.” An entire finger or toe swells uniformly so that you can no longer distinguish individual joint swelling. Dactylitis tends to show up asymmetrically, affects the toes more than the fingers, and can be either acutely painful (red, hot, tender) or chronic (puffy but not particularly sore). It’s considered a marker of more severe disease because it’s associated with permanent damage to the joints in that digit if left untreated.
Enthesitis, or inflammation where tendons and ligaments attach to bone, occurs in about 35% of people with psoriatic arthritis. The Achilles tendon and the sole of the foot (plantar fascia) are the most commonly affected sites. You’ll feel localized tenderness, soreness, or sharp pain at the attachment point, sometimes with visible swelling or redness.
Nail changes are extremely common, appearing in roughly 80% of people with psoriatic arthritis. These include small pits or dents in the nail surface, lifting of the nail from the nail bed, thickening, and crumbling. The nails are physically connected to the same tendon structures that attach near the fingertip joints, which helps explain why nail disease and joint disease in the fingers so often appear together.
How It Differs From Rheumatoid Arthritis
Because both conditions cause swollen, painful joints, psoriatic arthritis is sometimes confused with rheumatoid arthritis. Several features help distinguish them. Rheumatoid arthritis is typically symmetric, affecting the same joints on both sides. It tends to involve the wrists, knuckles, and middle finger joints. Psoriatic arthritis more often hits the joints closest to the fingertips, the lower back, and the sacroiliac joints.
Blood tests also differ. About 80% of people with rheumatoid arthritis test positive for rheumatoid factor and another antibody called anti-CCP. People with psoriatic arthritis are usually negative for both, which is why the condition is called “seronegative.” Imaging reveals different patterns too: rheumatoid arthritis causes bone erosion without new bone growth, while psoriatic arthritis can show both erosion and irregular new bone formation near joint margins. Dactylitis occurs in up to 50% of people with psoriatic arthritis but only about 5% of those with rheumatoid arthritis. Enthesitis is similarly uncommon in rheumatoid arthritis.
How It’s Diagnosed
There’s no single blood test for psoriatic arthritis. Doctors use a combination of clinical findings, lab work, and imaging. The most widely used framework is the CASPAR criteria, which require evidence of inflammatory joint, spine, or tendon disease plus at least three points from a scoring system. Points come from having current or past psoriasis, nail changes, a negative rheumatoid factor test, current or past dactylitis, and X-ray evidence of new bone formation near the joints of the hands or feet.
In practice, diagnosis often hinges on recognizing the pattern: joint symptoms plus skin or nail psoriasis, plus the absence of the antibodies found in rheumatoid arthritis. Imaging with MRI can reveal enthesitis and early bone changes that plain X-rays miss, which is useful when symptoms are subtle or the diagnosis is uncertain.
Who Develops It
A large meta-analysis pooling data from multiple studies found that about 19.7% of people with psoriasis eventually develop psoriatic arthritis. When stricter diagnostic criteria were applied, that number climbed to nearly 24%. In children and adolescents, the rate is much lower, around 3.3%. Among adults with psoriasis, new cases develop at a rate of roughly 0.3 to 2.7 per 100 people per year, meaning the risk accumulates steadily over time. In most people, the skin disease appears years before the joint symptoms, but in a small percentage, joint problems come first.
Cardiovascular and Metabolic Risks
Psoriatic arthritis is not just a joint disease. The same systemic inflammation that attacks joints and skin also affects blood vessels and metabolism. The majority of newly diagnosed patients already carry a greater than 10% risk of a cardiovascular event within 10 years, and the actual rate of heart attacks and strokes turns out to be nearly double what standard risk calculators predict.
Compared to people who have skin psoriasis alone, those with psoriatic arthritis face up to 50% higher odds of developing type 2 diabetes. Rates of high blood pressure, obesity, high cholesterol, and cardiovascular events are 1.5 to 2.6 times higher than in people with psoriasis without joint involvement. Inflammatory bowel disease and uveitis (a painful eye inflammation) also occur more frequently. These overlapping conditions are driven by the same underlying immune dysfunction, which is why controlling inflammation broadly, rather than just managing pain, is a central goal of treatment.
Treatment Options
Treatment for psoriatic arthritis aims to reduce inflammation, relieve symptoms, prevent joint damage, and address the skin disease simultaneously. The approach usually follows a step-up strategy, starting with less intensive therapies and escalating if the disease isn’t adequately controlled.
The first step for many people is a conventional disease-modifying drug, most commonly methotrexate. These medications work by broadly suppressing immune activity. They can help with joint swelling and skin symptoms, but they have limited evidence for treating spinal inflammation or enthesitis.
When conventional medications aren’t enough, biologic therapies target specific parts of the inflammatory chain. Some block a key inflammatory molecule called TNF, which plays a central role in joint destruction. Others target the signaling molecules that drive the abnormal immune cell activity responsible for both skin and joint inflammation. Each class has somewhat different strengths: some work particularly well for skin, others for spine involvement, and others for enthesitis and dactylitis. Choosing among them depends on which symptoms dominate and how the body responds.
A newer class of oral medications works by blocking specific enzymes inside immune cells, interrupting the signaling pathways that sustain inflammation. These offer an alternative for people who prefer pills over injections or who haven’t responded to biologics. Another oral option works through a different enzyme pathway and tends to be milder in effect, sometimes used for less severe disease.
Regardless of the medication, the goal is the same: get inflammation under control early enough to prevent the irreversible joint erosion and bone changes that accumulate over time. Physical therapy, regular exercise, and maintaining a healthy weight also play important roles in preserving joint function and reducing cardiovascular risk.